Cencora (COR) Stock
Large global pharmaceutical distributor with specialty pharmacy services. Here's the price, business snapshot, and what's worth knowing about Cencora in June 2026.
Cencora Inc (ticker: COR) is a large, global healthcare services and pharmaceutical distribution company. It connects drug manufacturers, pharmacies and healthcare providers through logistics, specialty pharmacy services, clinical trial support and data-driven solutions. With a market capitalisation around $63.8bn, Cencora’s scale gives it bargaining power and steady cash flow from distribution margins, while growth is increasingly driven by specialty medicines, managed services and partnerships with biopharma clients. Investors should note key strengths — diversified service lines, scale benefits and recurring revenue — alongside risks: tight industry margins, regulatory and compliance exposure, concentration with major manufacturer partners and sensitivity to reimbursement and inventory cycles. Past performance is not a guide to the future; values can rise and fall. This summary is general educational information, not personalised investment advice. If you’re considering Cencora for your portfolio, weigh your own risk tolerance, time horizon and seek regulated financial advice where appropriate.
Why It’s Moving
Cencora’s upbeat analyst backdrop is keeping COR in focus as investors look past short-term noise
- Analyst coverage remains broadly positive, with consensus views clustering around a Strong Buy or Buy rating, which is helping support sentiment around the shares.
- Recent target revisions and forecasts still imply meaningful upside versus the current trading range, reinforcing the market’s view that earnings power and cash generation remain resilient.
- In the absence of a major earnings release or company announcement this week, traders are leaning on sector stability and the stock’s defensive profile, which tends to attract interest when markets want lower-volatility exposure.
Cencora’s upbeat analyst backdrop is keeping COR in focus as investors look past short-term noise
- Analyst coverage remains broadly positive, with consensus views clustering around a Strong Buy or Buy rating, which is helping support sentiment around the shares.
- Recent target revisions and forecasts still imply meaningful upside versus the current trading range, reinforcing the market’s view that earnings power and cash generation remain resilient.
- In the absence of a major earnings release or company announcement this week, traders are leaning on sector stability and the stock’s defensive profile, which tends to attract interest when markets want lower-volatility exposure.
When is the next earnings date for CENCORA INC (COR)?
Cencora (COR) has not formally confirmed its next earnings date, but the consensus estimate is August 5, 2026. The upcoming report is expected to cover Q3 fiscal 2026. This timing is consistent with the company’s usual early-August earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cencora's stock with a target price of $392.6, indicating significant growth potential.
Financial Health
Cencora Inc. shows stable revenue and cash flow but has low profit margins.
Dividend
CENCORA INC's dividend yield of 0.88% is relatively low, indicating limited returns for dividend-focused investors. If you invested $1000 you would be paid $8.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring COR
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: 29 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Distribution backbone
Large-scale pharmaceutical distribution underpins steady revenues and cash flow, though margins can be thin and sensitive to reimbursement changes.
Global supply links
Extensive logistics and manufacturer relationships offer reach and resilience, while regulatory and compliance oversight remains an ongoing risk.
Specialty medicines growth
Specialty pharmacy and biopharma services are higher-margin growth areas, but success depends on execution and evolving healthcare policies.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
